Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardinal Manufactures 10% Gain In 1Q: Rx Stocks Stay Out Of Favor

Executive Summary

Cardinal's expanding manufacturing capacity is enhancing its image with investors who are attracted to the pharmaceutical sector but wary of the risks of drug development

You may also be interested in...



Iraq War Rally Helps Rx Stocks; Investors Adjust To Diminished Expectations?

Pfizer's steady progress toward closing the Pharmacia acquisition is giving the company a winning profile on Wall Street against the backdrop of a broader market rally fueled by the U.S. war in Iraq

Iraq War Rally Helps Rx Stocks; Investors Adjust To Diminished Expectations?

Pfizer's steady progress toward closing the Pharmacia acquisition is giving the company a winning profile on Wall Street against the backdrop of a broader market rally fueled by the U.S. war in Iraq

Cardinal To Run Xigris Emergency Distribution Via Acquisition Of Syncor

Cardinal will be the emergency supplier of Lilly's sepsis agent Xigris following the wholesaler's acquisition of the nuclear pharmacy company Syncor

Related Content

UsernamePublicRestriction

Register

PS039607

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel